Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Basilea Pharmaceutica (SWX:BSLN) is back in focus after reporting half year 2026 results on 18 August, with higher revenue and net income, and issuing upgraded full year revenue and operating profit guidance.
See our latest analysis for Basilea Pharmaceutica.
The earnings beat and raised guidance have coincided with a sharp pickup in momentum for Basilea Pharmaceutica, with a 30 day share price return of 25.19% and a 1 year total shareholder return of 38.11%.
If this kind of move has your attention, it could be a good moment to broaden your watchlist and check out 111 top founder-led companies .
The recent jump in Basilea Pharmaceutica after stronger half year figures and higher guidance can reflect genuine confidence in the business or a burst of optimism that runs ahead of fundamentals. How does the current valuation look in that context?
Price-to-Earnings of 15.5x: Is it justified?
Basilea Pharmaceutica currently trades on a P/E of 15.5x, which sits below both the Swiss market average of 19.9x and the European biotechs industry average of 22.9x.
The P/E ratio compares the company's share price to its earnings per share. It reflects what investors are paying today for each unit of current profit. For a commercial stage biotech with CHF247.4m of revenue and CHF52.4m of net income, this metric gives a quick sense of how the market is weighing its profitability against peers.
Analysts see earnings growing, although forecast profit growth of 0.74% per year and an expected revenue decline of 3.7% per year do not point to an aggressive growth profile. In that context, a P/E of 15.5x that also sits below an estimated fair P/E of 16.5x suggests the current pricing could move closer to that fair ratio if the company meets expectations.
Basilea Pharmaceutica's P/E looks restrained compared to a peer average of 92.1x for similar companies in the biotech space and sits below the European biotechs industry average of 22.9x. Compared with the estimated fair P/E of 16.5x for Basilea Pharmaceutica specifically, the current multiple implies the market is assigning a slightly lower earnings multiple than that fair level, despite a high historical return on equity of 32.3% and a track record of becoming profitable over the past 5 years.
Explore the SWS fair ratio for Basilea Pharmaceutica
Result: Price-to-Earnings of 15.5x (ABOUT RIGHT)
However, Basilea Pharmaceutica still faces risks around its late stage pipeline execution, as well as the annual revenue decline of 3.7%, which could challenge the current narrative.
Find out about the key risks to this Basilea Pharmaceutica narrative.
Another view on Basilea Pharmaceutica's value
The SWS DCF model paints a different picture to the P/E work. On this view, Basilea Pharmaceutica at CHF65.6 is trading above an estimated future cash flow value of CHF61.84. This points to the stock looking mildly overvalued rather than cheap. Which signal should you weigh more heavily?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Basilea Pharmaceutica for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 278 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Feeling mixed about Basilea Pharmaceutica after all this numbers heavy context and differing signals. Act while the details are fresh in your mind and weigh both sides by checking the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Basilea Pharmaceutica?
If Basilea Pharmaceutica has sharpened your focus, this is the moment to widen your scope and line up fresh ideas before the next move catches you off guard.
-
Target income strength by checking out reliable high yield opportunities through the 432 dividend fortresses that can complement a growth focused portfolio.
-
Hunt for value by scanning the 278 high quality undervalued stocks that pair strong fundamentals with pricing that may not fully reflect their financial profile yet.
-
Prioritise resilience by reviewing the 294 resilient stocks with low risk scores that can help anchor your portfolio when sentiment turns fickle.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BSLN.SW .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
